1. Home
  2. CDT vs DEVS Comparison

CDT vs DEVS Comparison

Compare CDT & DEVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • DEVS
  • Stock Information
  • Founded
  • CDT 2019
  • DEVS N/A
  • Country
  • CDT United States
  • DEVS Canada
  • Employees
  • CDT N/A
  • DEVS N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • DEVS
  • Sector
  • CDT Health Care
  • DEVS
  • Exchange
  • CDT Nasdaq
  • DEVS NYSE
  • Market Cap
  • CDT 5.3M
  • DEVS 6.1M
  • IPO Year
  • CDT N/A
  • DEVS N/A
  • Fundamental
  • Price
  • CDT $0.39
  • DEVS $0.53
  • Analyst Decision
  • CDT
  • DEVS
  • Analyst Count
  • CDT 0
  • DEVS 0
  • Target Price
  • CDT N/A
  • DEVS N/A
  • AVG Volume (30 Days)
  • CDT 768.1K
  • DEVS 42.7M
  • Earning Date
  • CDT 05-15-2025
  • DEVS 05-27-2025
  • Dividend Yield
  • CDT N/A
  • DEVS N/A
  • EPS Growth
  • CDT N/A
  • DEVS N/A
  • EPS
  • CDT N/A
  • DEVS N/A
  • Revenue
  • CDT N/A
  • DEVS N/A
  • Revenue This Year
  • CDT N/A
  • DEVS N/A
  • Revenue Next Year
  • CDT N/A
  • DEVS N/A
  • P/E Ratio
  • CDT N/A
  • DEVS N/A
  • Revenue Growth
  • CDT N/A
  • DEVS N/A
  • 52 Week Low
  • CDT $0.51
  • DEVS $0.18
  • 52 Week High
  • CDT $350.00
  • DEVS $1.91
  • Technical
  • Relative Strength Index (RSI)
  • CDT 31.63
  • DEVS N/A
  • Support Level
  • CDT $0.38
  • DEVS N/A
  • Resistance Level
  • CDT $0.41
  • DEVS N/A
  • Average True Range (ATR)
  • CDT 0.04
  • DEVS 0.00
  • MACD
  • CDT 0.01
  • DEVS 0.00
  • Stochastic Oscillator
  • CDT 9.89
  • DEVS 0.00

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About DEVS DEVVSTREAM CORP

DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

Share on Social Networks: